Permian Basin Royalty Trust (PBT) To Go Ex-Dividend on October 31st
by Teresa Graham · The Cerbat GemPermian Basin Royalty Trust (NYSE:PBT – Get Free Report) announced a monthly dividend on Monday, October 21st, Wall Street Journal reports. Stockholders of record on Thursday, October 31st will be paid a dividend of 0.03 per share by the oil and gas producer on Friday, November 15th. This represents a $0.36 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date of this dividend is Thursday, October 31st.
Permian Basin Royalty Trust has increased its dividend payment by an average of 36.7% per year over the last three years.
Permian Basin Royalty Trust Trading Up 0.5 %
Shares of NYSE:PBT opened at $11.67 on Wednesday. Permian Basin Royalty Trust has a 1 year low of $10.14 and a 1 year high of $20.61. The stock has a 50-day simple moving average of $11.43 and a 200-day simple moving average of $11.67.
Permian Basin Royalty Trust (NYSE:PBT – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The oil and gas producer reported $0.18 earnings per share for the quarter. The firm had revenue of $8.83 million during the quarter. Permian Basin Royalty Trust had a return on equity of 15,940.96% and a net margin of 96.28%.
Permian Basin Royalty Trust Company Profile
Permian Basin Royalty Trust, an express trust, holds royalty interests in various oil and gas properties in the United States. The company holds a 75% net overriding royalty interest in the Waddell Ranch properties, including Dune, Sand Hills (Judkins), Sand Hills (McKnight), Sand Hills (Tubb), University-Waddell (Devonian) and Waddell fields in Crane County, Texas.
Further Reading
- Five stocks we like better than Permian Basin Royalty Trust
- Dividend Capture Strategy: What You Need to Know
- Cisco: Why Analysts Are Targeting 35% Gains by Christmas
- When to Sell a Stock for Profit or Loss
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Bank Stocks – Best Bank Stocks to Invest In
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?